PSA Testing Before TRT: Why A Baseline PSA Level Matters

PSA testing before TRT is a standard safety step built into every major clinical guideline for testosterone replacement therapy. The American Urological Association (AUA) identifies baseline PSA measurement in men over 40 as a Clinical Principle before starting testosterone, and the Endocrine Society recommends against initiating therapy when PSA exceeds specific thresholds without urologic evaluation (Mulhall et al., 2018; Bhasin et al., 2018). Men considering testosterone therapy through a direct-pay lab testing provider should understand what PSA screening involves, why it matters, and what the numbers actually mean.

A baseline PSA blood test measures prostate-specific antigen, a protein produced by prostate cells. PSA is a prostate health marker, not a cancer test. Elevated levels can reflect benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, or prostate cancer. The baseline number itself is less important than the change from that number over time, which is why checking it before starting testosterone sets the reference point for all future monitoring.

The same guidelines that call for baseline PSA also carry a separate, equally clear statement: there is no demonstrated link between testosterone replacement therapy and the development of new prostate cancer in properly screened men. AUA Statement 17 calls this a Strong Recommendation backed by Grade B evidence (Mulhall et al., 2018). The baseline PSA is a safety measure. Ordering it does not imply that testosterone causes cancer.

Why Do Guidelines Require a Baseline PSA Before Testosterone?

The AUA testosterone deficiency guideline, Statement 12, directs clinicians to measure PSA in men over 40 before starting therapy to exclude an undiagnosed prostate cancer (Mulhall et al., 2018). That statement answers a practical question: if a man already has an elevated PSA, his clinician needs to investigate before adding an androgen.

The Endocrine Society recommends against starting testosterone in men with PSA above 4 ng/mL, or above 3 ng/mL in men at higher prostate-cancer risk (Black men and men with a first-degree relative diagnosed with prostate cancer), without a urologic evaluation first (Bhasin et al., 2018). These cutoffs aren't arbitrary. They reflect a risk-stratified approach that separates men who can proceed safely from men who need further workup.

Men who want to check where they stand before an initial consultation can order testosterone lab panels that include total and free testosterone alongside related markers.

Two questions often get mixed together in consumer-facing articles:

1. Does testosterone therapy cause new prostate cancer?

2. Should a man have a PSA test before his first dose?

Guidelines answer the second question with a clear yes for men over 40 and for higher-risk men at younger ages. They answer the first with a qualified no, supported by the largest randomized trial in the field.

Does TRT Cause Prostate Cancer?

The TRAVERSE trial is the largest randomized, placebo-controlled study of testosterone replacement therapy to date. It enrolled 5,246 men aged 45-80 with two fasting testosterone values below 300 ng/dL, hypogonadal symptoms, and preexisting cardiovascular disease or elevated cardiovascular risk (Lincoff et al., 2023).

The TRAVERSE prostate safety substudy, published separately, analyzed 5,204 of those men over 14,304 person-years of follow-up. High-grade prostate cancer (Gleason 4+3 or higher) occurred in 5 of 2,596 men on testosterone (0.19%) compared with 3 of 2,602 men on placebo (0.12%). The hazard ratio was 1.62, but the 95% confidence interval ranged from 0.39 to 6.77, and the P value was 0.51 (Bhasin et al., 2023). Any prostate cancer was 0.46% vs 0.42%. Acute urinary retention, invasive prostate procedures, and new drug treatment for lower urinary tract symptoms showed no statistically significant differences.

Those numbers carry a specific boundary. TRAVERSE excluded men with known prostate cancer, prostate nodules, or elevated screening PSA. The low event rate may not apply to unscreened men or men with existing prostate disease. Follow-up measured years, not decades.

The same AUA guideline that requires baseline PSA (Statement 12) also tells clinicians to inform clients of the absence of evidence linking testosterone therapy to prostate cancer development (Statement 17, Strong Recommendation, Grade B). Both statements come from the same document, separated by a few pages. They answer different questions.

When citing TRAVERSE cardiovascular data, the secondary signals must accompany the neutral primary endpoint. Primary MACE was 7.0% on testosterone vs 7.3% on placebo (HR 0.96, 95% CI 0.78-1.17). Atrial fibrillation was higher at 3.5% vs 2.4% (P=0.02), acute kidney injury at 2.3% vs 1.5% (P=0.04), and pulmonary embolism at 0.9% vs 0.5% (Lincoff et al., 2023).

How Much Does PSA Rise After Starting Testosterone?

Mean PSA rises modestly after testosterone therapy begins. This is expected physiology and does not by itself indicate cancer.

In TRAVERSE, mean PSA rose 0.20 ng/mL on testosterone gel compared with 0.08 ng/mL on placebo (P<0.001). The gap did not widen after 12 months (Bhasin et al., 2023). For context, the Endocrine Society's referral trigger during year 1 is a confirmed rise greater than 1.4 ng/mL above baseline, or a confirmed PSA above 4.0 ng/mL. The mean TRAVERSE rise of 0.20 ng/mL sits well below that threshold.

The saturation model offers a mechanistic explanation. Morgentaler and Traish proposed that androgen-driven prostate PSA output rises when testosterone moves from well below approximately 250 ng/dL (about 8 nmol/L) toward that range, then flattens as androgen receptors reach capacity (Morgentaler & Traish, 2009). A man whose pretreatment testosterone is 150 ng/dL may see a larger early PSA bump than a man whose testosterone is already 280 ng/dL.

That model is a mechanistic framework, not proof that every PSA rise is harmless. For men interested in how their own tissue responds to androgens, androgen receptor testing measures sensitivity at the receptor level. A confirmed jump that crosses guideline referral lines requires a urologic evaluation, regardless of the explanation.

Clients who want a dedicated PSA lab test can add total, free, and percent-free PSA to any draw.

What PSA Level Stops a Man from Starting TRT?

No single number applies to every man. The Endocrine Society recommends a two-tier threshold:

• PSA above 4 ng/mL in any man: the Endocrine Society recommends against starting testosterone without urologic evaluation.

• PSA above 3 ng/mL in men at higher prostate-cancer risk (Black men, men with a first-degree relative diagnosed with prostate cancer): the same recommendation applies.

These thresholds trigger further evaluation, not automatic disqualification. The treating clinician and client determine next steps through shared decision-making. If the urologic workup (which may include repeat PSA, multiparametric MRI, and, when indicated, prostate biopsy) clears the man, testosterone therapy may proceed with closer monitoring.

The AUA early-detection guideline adds a separate instruction: repeat a newly elevated PSA before reflexing to biomarkers, imaging, or biopsy (Wei et al., 2023). Transient causes of PSA elevation (ejaculation within 48 hours, urinary tract infection, vigorous prostate manipulation) can produce a lab result that disappears on retest.

Men preparing for baseline blood work should note that PSA samples follow the same early-morning fasting protocol as testosterone draws, and abstaining from ejaculation for 48 hours before the test reduces the chance of a transient spike.

What Does PSA Monitoring Look Like During TRT?

The Endocrine Society outlines a first-year monitoring plan for testosterone therapy that includes PSA:

• Evaluate prostate-cancer risk before starting treatment.

• Recheck PSA at 3-12 months after starting.

• Refer to urology during year 1 if there is a confirmed PSA increase above 1.4 ng/mL from baseline, a confirmed PSA above 4.0 ng/mL, or a new prostatic abnormality on digital rectal examination.

• After year 1, follow standard age- and risk-based screening guidelines using shared decision-making.

"Standard screening" after year 1 means the AUA/SUO 2023 early-detection recommendations: regular screening every 2-4 years for men aged 50-69 who choose to be screened, with earlier start and individualized intervals for higher-risk men (Wei et al., 2023). Testosterone therapy doesn't require PSA every 8 weeks for life.

Pre-built lab testing panels that include PSA alongside testosterone, hematocrit, estradiol, and metabolic markers can simplify follow-up draws.

How Do Screening Recommendations Compare Across Guidelines?

The AUA testosterone guideline and the USPSTF prostate-screening recommendation sometimes appear to conflict, especially for men aged 40-54 at average risk. They're answering different questions.

The AUA testosterone guideline requires a baseline PSA in men over 40 because starting an androgen is a clinical action that needs a safety check. The USPSTF addresses whether to screen the general population. A 42-year-old man at average risk may not meet the USPSTF threshold for routine screening, but if he's about to start testosterone, the AUA instructs his clinician to draw a PSA so that later on-treatment changes can be interpreted against a known starting point.

What Changed in FDA Labeling for Testosterone Products?

FDA labeling for testosterone products went through two changes relevant to prostate monitoring:

The February 28, 2025 class-wide action removed the previous cardiovascular boxed-warning language following the TRAVERSE trial, added a blood-pressure warning, and retained the Limitation of Use statement that safety and efficacy in age-related hypogonadism have not been established. The prostate-cancer contraindication (known or suspected carcinoma of the prostate) remained intact (FDA, 2025).

On June 18, 2026, HHS requested that manufacturers update labels to narrow the prostate-cancer contraindication to metastatic disease, remove the Limitation of Use for age-related hypogonadism, and soften the BPH warning (HHS, 2026). The agency's language explicitly retained the recommendation that clinicians assess risk, screen before treatment, and monitor during therapy.

The June 2026 action is a request, not a completed relabeling. Until each product's updated label appears on DailyMed, the current label language governs. Clients can confirm which label applies to the specific product dispensed by their clinician.

Is TRT Safe for Men with BPH?

Some evidence links testosterone deficiency to BPH and associated lower urinary tract symptoms, though the relationship is not fully established. The clinical question is whether adding testosterone to a man with existing BPH worsens his symptoms.

In the TRAVERSE prostate substudy, International Prostate Symptom Score (IPSS) changes showed no significant difference between testosterone and placebo groups (Bhasin et al., 2023). Current FDA label language still advises monitoring for worsening BPH signs and symptoms, and the June 2026 HHS request proposed softening that warning to continued monitoring in severe symptomatic disease.

For men with existing BPH who are considering testosterone, the decision is individualized and involves shared decision-making between the client and clinician, weighing the documented deficiency against urinary symptoms with periodic IPSS reassessment.

Can Men with a History of Prostate Cancer Use TRT?

This is specialist territory. AUA Statement 18 states that evidence is inadequate to quantify the risk-benefit ratio of testosterone therapy in men with a history of prostate cancer. The decision is individualized and should involve urology (Mulhall et al., 2018).

Current FDA labels contraindicate testosterone in men with known or suspected prostate cancer. The June 2026 HHS request proposed narrowing that to metastatic disease. That request has not yet resulted in a completed class-wide relabeling.

Select international urology guidelines allow consideration after treated localized disease in selected men, usually after a waiting period and with an undetectable or stable PSA, under specialist supervision. This is not a telehealth default. Men in this situation should work with a urologist alongside their prescribing clinician.

What Labs Should Be Drawn Before Starting Testosterone Therapy?

PSA is one marker in a larger pretreatment panel. The AUA and Endocrine Society guidelines together outline a minimum set:

• Two separate early-morning (8-10 AM) testosterone draws, 1-3 weeks apart, from the same lab and assay, fasting. A diagnosis of testosterone deficiency requires confirmed low levels plus compatible signs and symptoms.

• Complete blood count with hematocrit (to set a baseline for monitoring erythrocytosis on treatment).

• PSA in men over 40 or in higher-risk men at younger ages.

• Digital rectal examination when clinically indicated, per the Endocrine Society pretreatment evaluation.

• LH and FSH when distinguishing primary from secondary hypogonadism is clinically relevant.

Individual biomarker testing allows clients to select specific markers when a full panel isn't needed. For a broader baseline before starting testosterone therapy, bundled lab panels that pair hormones with metabolic, hematologic, and prostate markers in a single draw can cover the guideline minimum and then some.

Men who want to understand how each biomarker fits into an overall picture can use the lab builder tool to customize a panel, and the how it works page walks through the ordering and draw process.

PSA testing before TRT doesn't add complexity to the start. It adds a number that makes every follow-up draw more useful, because the clinician can compare the new PSA to the man's own pretreatment value rather than guessing whether a later reading is new or old.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine. 

FAQs

Should PSA be checked before the first testosterone prescription?

The AUA directs clinicians to measure PSA in men over 40 before starting testosterone therapy (Statement 12, Clinical Principle). The Endocrine Society recommends against starting if PSA is above 4 ng/mL, or above 3 ng/mL in higher-risk men, without urologic evaluation (Mulhall et al., 2018; Bhasin et al., 2018). Both guidelines treat the baseline PSA as a safety measure, not an indication that testosterone causes cancer.

Does a baseline PSA mean testosterone causes prostate cancer?

No. AUA Statement 17 states that clinicians should inform clients of the absence of evidence linking testosterone therapy to prostate cancer development (Strong Recommendation, Grade B). The baseline PSA exists so that later on-treatment changes have a comparison number.

How much does PSA typically rise on TRT?

In the TRAVERSE trial, mean PSA rose 0.20 ng/mL on testosterone gel compared with 0.08 ng/mL on placebo. The gap did not widen after 12 months (Bhasin et al., 2023). The Endocrine Society refers to urology in year 1 for a confirmed rise above 1.4 ng/mL from baseline or a confirmed PSA above 4.0 ng/mL.

Can testosterone therapy begin if PSA is elevated?

Elevated PSA requires a urologic evaluation before testosterone starts. If the workup excludes malignancy, therapy may proceed under closer monitoring. The treating clinician and client determine next steps through shared decision-making (Bhasin et al., 2018).

Did the TRAVERSE trial prove TRT is safe for the prostate?

TRAVERSE showed low prostate-cancer event rates in screened hypogonadal men: high-grade prostate cancer at 0.19% vs 0.12% (HR 1.62, 95% CI 0.39-6.77, P=0.51) over 14,304 person-years. That result applies to men screened to exclude known cancer and elevated PSA. It is not a lifetime guarantee, and follow-up is years, not decades (Bhasin et al., 2023).

How often is PSA tested during testosterone therapy?

The Endocrine Society recommends rechecking PSA at 3-12 months after starting, with urology referral if confirmed PSA exceeds the year-1 triggers. After year 1, men follow standard age- and risk-based screening using shared decision-making (AUA/SUO 2023: every 2-4 years for men aged 50-69 who choose to be screened).

If PSA goes up in the first 3 months, does that mean cancer?

A small early rise is documented in TRAVERSE and predicted by the saturation model when pretreatment testosterone is well below approximately 250 ng/dL. Cancer concern rises when the increase is confirmed and crosses the Endocrine Society year-1 referral lines (above 1.4 ng/mL from baseline or above 4.0 ng/mL), or when a new prostate abnormality appears on examination (Morgentaler & Traish, 2009).

References

• J Urol. 2018;200(2):423-432

• J Clin Endocrinol Metab. 2018;103(5):1715-1744

• JAMA Netw Open. 2023;6(12):e2348692

• N Engl J Med. 2023;389:107-117

• FDA Class-Wide Labeling Changes for Testosterone Products, February 2025

• HHS Requested Testosterone Labeling Updates, June 2026

• J Urol. 2023;210(1):46-53

• Eur Urol. 2009;55(2):310-320